After 1 µM ouabain pretreatment for 1 h, glycolytic extracellular acidification decreased by 52% in MDA-MB-231 and 38% in MCF-7 cells. The 21% decrease in HCC1954 cells did not reach significance, and murine 4T1 cells showed no significant change. Oxygen consumption was unchanged across the panel; a parallel acute viability assay found no significant loss of membrane integrity. [2]
Structural basis of ouabain binding to phosphorylated Na+,K+-ATPase
Biochemical assay · Purified pig-kidney Na+,K+-ATPase α1β1γ complex in the E2P state [1]
The ouabain-bound structure places the ligand between transmembrane segments αM1–6, with its lactone directed into the membrane and polar steroid contacts to αM1, αM2 and αM6. The authors interpret binding as stabilization of the E2P conformation.
Literature-Reported Treatment Conditions
- Treatment concentration
- 0.5 mM ouabain in membrane preincubation for crystallization
- Method
- X-ray crystallography of the ouabain-stabilized E2P complex; crystallization at 19 °C
- Co-treatment
- Inorganic phosphate and Mg2+ used to stabilize the enzyme state; a purified-protein preparation.
- Reported limits
- Ouabain supplier, lot, hydration state and preincubation duration are not specified in the inspected main-text methods. Crystallization concentration is not an inhibitory potency.
Methods and source locations
Compound reported in the paper: Ouabain; Compound label in the paper: ouabain
Ouabain compound-level evidence; no salt/hydrate conversion, stereoisomer substitution, or validation of the current Adooq lot.
Figure 1B–E; Results and Discussion—Ouabain Binding Site; Materials and Methods—Crystallization and Data Collection; Structure Determination and Analysis
Resolution of the ouabain-bound enzyme structure: Molecular replacement, model refinement and electron-density interpretation — Introduction final paragraph; Materials and Methods—Structure Determination and Analysis; Figure 1C
Ouabain position and interactions: Electron-density maps and structural model; no mutation experiment in this record. — Results and Discussion—Ouabain Binding Site; Figure 1C
Cation-dependent apparent affinity of ouabain for the E2P enzyme
Biochemical assay · Purified pig-kidney Na+,K+-ATPase E2P membrane preparation [1]
Potassium lowered the reported affinity for ouabain; increasing Mg2+ partially countered that effect. The calculated dissociation constants describe defined cation conditions rather than a universal IC50.
Literature-Reported Treatment Conditions
- Treatment concentration
- Ouabain titration shown over 0–3 µM in Figure 3A; 3 or 12 mM MgCl2 with or without 10 mM KCl
- Method
- Equilibrium ouabain-binding analysis read out through residual ATPase activity
- Co-treatment
- Cation-condition comparisons: 3 mM MgCl2 without KCl; 3 mM MgCl2 plus 10 mM KCl; 12 mM MgCl2 plus 10 mM KCl.
- Reported limits
- Binding temperature, incubation time and full fitting/protocol details are delegated to the cited Yatime et al. 2011 method and were not retrieved here; no further assay conditions are inferred.
Methods and source locations
Compound reported in the paper: Ouabain; Compound label in the paper: ouabain
Ouabain compound-level evidence; no salt/hydrate conversion, stereoisomer substitution, or validation of the current Adooq lot.
Figure 3A and caption; cation-competition discussion; Materials and Methods—Enzyme Preparation and Biochemical Experiments
Ouabain affinity without added KCl: Equilibrium binding / residual activity; Figure 3 data points are averages of at least three experiments ± SEM. — Figure 3A and caption; Materials and Methods—Enzyme Preparation and Biochemical Experiments
Ouabain affinity with 10 mM KCl at lower MgCl2: Same equilibrium comparison; reported fitted Kd, not a graph-derived IC50. — Figure 3A caption
Ouabain affinity with 10 mM KCl at higher MgCl2: Same equilibrium comparison; reported fitted Kd. — Figure 3A caption
Acute ouabain treatment alters glycolytic acidification in a model-dependent manner
Cell-based study · Human MDA-MB-231, HCC1954 and MCF-7 breast-cancer cells; murine 4T1 breast-cancer cells [2]
After 1 µM ouabain pretreatment for 1 h, glycolytic ECAR decreased significantly in MDA-MB-231 and MCF-7 cells. The HCC1954 decrease did not reach significance, and 4T1 ECAR was unchanged. OCR did not differ significantly in any of the four cell lines. A parallel 1-h trypan-blue assay found no significant acute viability loss.
Literature-Reported Treatment Conditions
- Treatment concentration
- 1 µM ouabain
- Exposure duration
- 1 h pretreatment; followed by medium exchange and 1 h equilibration before the Seahorse stress test
- Method
- Seahorse XFe24 glycolytic stress test; ECAR normalized to well DNA content using DRAQ5
- Vehicle
- No-ouabain control; ouabain stock solvent not specified in the inspected treatment methods.
- Co-treatment
- Ouabain pretreatment alone. Subsequent assay challenges: 10 mM glucose, 1 µM oligomycin and 100 mM 2-deoxy-D-glucose; these define the stress test rather than an anticancer combination treatment.
- Reported limits
- Hydration state, lot and ouabain stock solvent are not established. Published Figure 2 supplement cross-references are inconsistent; the relevant definitions and other-cell traces were located directly in SI Figures S7 and S9.
Methods and source locations
Compound reported in the paper: Ouabain; Compound label in the paper: ouabain
Ouabain compound-level evidence; no salt/hydrate conversion, stereoisomer substitution, or validation of the current Adooq lot.
Methods—Cell culture and treatment protocols (Sec3), Trypan blue exclusion (Sec6), Extracellular Flux (Sec10); Results Sec17 and Sec19; Figures 1h and 2; publisher SI Figures S7 and S9
Glucose-stimulated glycolytic ECAR in MDA-MB-231 cells: Figure 2e; nested unpaired t-test; n = 3 biological repeats, each with n = 3 technical repeats. — Figure 2e caption; Results—Treatment effect of ouabain on extracellular acidification rate (Sec19)
Glucose-stimulated glycolytic ECAR in MCF-7 cells: Figure 2g; nested unpaired t-test; same biological/technical replication as Figure 2. — Figure 2g caption
Glucose-stimulated glycolytic ECAR in HCC1954 cells: Figure 2f; nested unpaired t-test; same replication as Figure 2. Not a significant reduction. — Figure 2f caption
Glucose-stimulated glycolytic ECAR in murine 4T1 cells: Figure 2d; nested unpaired t-test; same replication as Figure 2. — Figure 2d caption
OCR during the glucose time window: Simultaneous OCR measurement; nested unpaired t-test; same replication as Figure 2. — Figure 2d–g caption
Membrane-integrity viability after acute treatment: Trypan-blue exclusion control; figure labels ns. Exact viability percentages and n are not inferred from points. — Figure 1h and caption; Methods—Trypan blue exclusion (Sec6); Results—Ouabain cytotoxicity (Sec17)